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Immunodeficiencies (IDs) are disorders of the immune system that increase susceptibility
to infections and cancer, and are therefore associated with elevated morbidity and
mortality. IDs can be primary (not caused by other condition or exposure) or secondary
due to the exposure to different agents (infections, chemicals, aging, etc.). Most primary
immunodeficiencies (PIDs) are of genetic origin, caused by mutations affecting genes
with key roles in the development or function of the cells of the immune system. A large
percentage of PIDs are associated with a defective development and/or function of
lymphocytes and, especially, B cells, the ones in charge of generating the different
types of antibodies. B-cell development is a tightly regulated process in which many
different factors participate. Among the regulators of B-cell differentiation, a correct
epigenetic control of cellular identity is essential for normal cell function. With the
advent of next-generation sequencing (NGS) techniques, more and more alterations
in different types of epigenetic regulators are being described at the root of PIDs,
both in humans and in animal models. At the same time, it is becoming increasingly
clear that epigenetic alterations triggered by the exposure to environmental agents
have a key role in the development of secondary immunodeficiencies (SIDs). Due
to their largely reversible nature, epigenetic modifications are quickly becoming key
therapeutic targets in other diseases where their contribution has been known for more
time, like cancer. Here, we establish a parallelism between IDs and the nowadays
accepted role of epigenetics in cancer initiation and progression, and propose that
epigenetics forms a “third axis” (together with genetics and external agents) to be
considered in the etiology of IDs, and linking PIDs and SIDs at the molecular level.
We therefore postulate that IDs arise due to a variable contribution of (i) genetic, (ii)
environmental, and (iii) epigenetic causes, which in fact form a continuum landscape
of all possible combinations of these factors. Additionally, this implies the possibility
of a fully epigenetically triggered mechanism for some IDs. This concept would have
important prophylactic and translational implications, and would also imply a more
blurred frontier between primary and secondary immunodeficiencies.
Keywords: epigenetics, primary immunodeficiencies, secondary immunodeficiencies, developmental syndromes,
environmental exposures, infections, aging
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INTRODUCTION
Human immunodeficiencies (IDs) are a large and heterogeneous
group of diseases whose common underlying feature is a
malfunctioning of the immune system that leads to an increased
susceptibility to infections, often associated with autoimmunity
and an elevated risk of cancer. Consequently, IDs have a
significant disease-associated morbidity and, in the most severe
cases, mortality. Broadly speaking, today, IDs are clinically
grouped into two large subtypes according to their etiology:
primary immunodeficiencies (PIDs), which are caused by
congenital conditions (Picard et al., 2018) (see below), and
secondary (acquired) immunodeficiencies (SIDs), which are
the result of exposure of the organism to exogenous factors
(infections, radiation, chemicals, aging, poor nutrition, etc.)
(Chinen and Shearer, 2010). Each group is in itself subdivided in
many different subtypes with distinct causes and varied clinical
manifestations, and classification of IDs can be performed on the
basis of very different criteria (clinical, molecular, cellular types
affected, etc.) (Sullivan and Stiehm, 2014).
Primary immunodeficiencies constitute a heterogeneous
group of more than 350 different disorders. They can appear
isolated, only affecting the immune function, but they also often
appear in the context of more complex multiorganic syndromes
with a plethora of other associated defects (syndromic IDs; Ming
et al., 2003). Most PIDs are of genetic origin and, with more
than 340 genes identified already, new PIDs are being described
in a rapidly increasing number (Bousfiha et al., 2018). The
majority of PIDs are caused by either spontaneous of hereditary
mutations affecting proteins with essential functions in the
development and/or function of the cells of the immune system.
The molecular pathways altered by these mutations can be many
(Bousfiha et al., 2018), and the mechanisms of action leading
to the final appearance of the immunodeficient phenotype can
be very varied; in fact, many of them have not been completely
clarified yet. Furthermore, the clinical spectrum of PIDs is very
heterogeneous, especially for the more complex syndromic IDs,
and the pathological consequences can affect both immune
and non-immune systems, and can range from just a reduced
response against some specific pathogen, to more serious
problems like autoimmunity and cancer (Liadaki et al., 2013).
Although different immune cell types can be affected in
PIDs, more than half of the diagnosed patients present with
antibody deficiencies (Bousfiha et al., 2018; Picard et al., 2018)
and, in the clinic, almost 90% of the patients suffer from defects
in B-cell differentiation (Liadaki et al., 2013), with disorders
like hyper-IgM (HIGM), common variable immunodeficiency
(CVID), selective IgA deficiency (IgAD), or IgG subclass
deficiency. Lymphocyte development (see below) is a tightly
regulated process requiring the synchronized collaboration of
external signals (cytokines, ligands, antigens, helper cells),
internal factors (epigenetic regulators, transcription factors, DNA
recombination-activating proteins), and housekeeping cellular
processes (proliferation, cell cycle, DNA repair). Therefore, the
alteration of any of these elements might lead to a malfunctioning
lymphocyte population. In the last years, a small but increasing
number of alterations in genes involved in the epigenetic control
of cellular identity and function (see below, and Table 1) have
been described at the root of IDs (Campos-Sanchez et al., 2019).
The role of epigenetic alterations in the origin and development
of other developmental pathologies like cancer has been well
established (Vicente-Duenas et al., 2013, 2018; Ntziachristos
et al., 2016), complementing the previous mutation-centric
interpretation of the disease. Furthermore, due to their largely
reversible nature, epigenetic modifications are quickly becoming
crucial therapeutic targets in cancer and other diseases (Berdasco
and Esteller, 2019; Jones et al., 2019). In this article, we review
the mounting evidences supporting a key role for epigenetics in
the origin and/or the progression of PIDs. Also, we describe how
secondary immunodeficiencies (SIDs) are caused by exposure
to external factors, and how the pathological effects of the
latter are very often mediated by interference with the normal
epigenetic regulation of the immune system. Also, in other
important pathologies of the immune system, like autoimmune
diseases (which often appear together with IDs), the importance
of epigenetic alterations is nowadays widely accepted [reviewed
in Hedrich and Tsokos (2011) and Mazzone et al. (2019)]. All
these facts support the hypothesis that epigenetic alterations are
a common factor that might underlie many cases of human IDs.
THE MAIN MOLECULAR PLAYERS OF
EPIGENETIC REGULATION
From the molecular point of view, nowadays the term
“epigenetics” refers to the biochemical processes that control the
establishment, maintenance, and inheritance of gene expression
patterns without altering the germline DNA sequence (Pirrotta,
2016, and references therein). Epigenetic regulators are therefore
in charge of monitoring that the different genes are expressed
in a correct developmental window and in a precise cellular
context, and they are in charge of maintaining the heritability
of gene expression patterns. Consequently, they are responsible
for establishing cell identity and function along cellular
development. Their main mechanism of action is the chemical
modification of DNA and histones (acetylation, methylation,
phosphorylation, etc.), and these modifications can be added
(“written”) or removed (“erased”) by different enzymes, and can
afterward be “read” by various effector proteins (Zhao and Garcia,
2015; Allis and Jenuwein, 2016). In this way, different chemical
epigenetic marks act in combination to generate a code that
controls the windows and levels of transcription of the different
genes. Besides these chemical modifications, other molecules
like non-coding RNAs (ncRNAs) contribute to determining the
patterns of gene expression during development by regulating
DNA and RNA properties. Finally, the hierarchical nature of
genome organization also makes that the proteins contributing
to the supra-structural organization of DNA can play a role in
the control of gene expression. In a brief overview, the most
important molecular epigenetic regulators are as follows.
DNA Methylation
DNA methylation is a chemical modification that transfers
a methyl group to the position 5 of cytosine in 5′CpG3′
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TABLE 1 | Epigenetic regulators altered in human primary immunodeficiencies.
Disease Abbreviation OMIM #Access Low
immunoglobulin
levels
Reduced B-cell
function/number
Reduced T-cell
function/number
Affected gene Epigenetic function affected
Immunodeficiency–centromeric
instability–facial anomalies syndrome 1
ICF1 OMIM 242860 Yes Yes Yes, with age DNMT3B De novo DNA methylation
Immunodeficiency–centromeric
instability–facial anomalies syndrome 2
ICF2 OMIM 614069 Yes, milder than
ICF1
Yes Yes ZBTB24 Maintenance of DNA
methylation
Immunodeficiency–centromeric
instability–facial anomalies syndrome 3
ICF3 OMIM 616910 Yes No Yes CDCA7 Maintenance of DNA
methylation
Immunodeficiency–centromeric
instability–facial anomalies syndrome 4
ICF4 OMIM 616911 Yes No Yes HELLS Chromatin remodeling
Maintenance of DNA
methylation
Wolf–Hirschhorn syndrome WHS OMIM 194190 Yes Yes Unclear 4p deletion,
WHSC1
Histone H3K36 mono- and
di-methylation
Kabuki syndrome 1 Kabuk1,
KS1
OMIM 147920 Yes Impaired terminal
differentiation
Reduced memory
B cells
Yes KMT2D Histone H3K4 trimethylation
Kabuki syndrome 2 Kabuk2,
KS2
OMIM 300867 Yes – – KDM6A (UTX ) Histone H3K27 demethylation
Kleefstra syndrome KLEFS1 OMIM 610253 – – – EHMT (GLP) Histone H3K9 mono- and
di-methylation
Wiedemann–Steiner syndrome WS OMIM 605130 Yes Yes – KMT2A (MLL) Histone H3K4 methylation
Schimke immuno-osseous dysplasia SIOD OMIM 242900 Yes No Yes SMARCAL1 Chromatin remodeling DNA
annealing helicase
INO80 in class-switch recombination
defects
CSR-D Yes Reduced memory
B cells
No INO80 Chromatin remodeling
CHARGE syndrome CHARGE OMIN 214800 Yes – Yes CHD7 Chromatin remodeling Helicase
Roifman syndrome Roifman OMIM 616651 Yes Yes – RNU4ATAC Non-coding RNA Splicing
Wiskott–Aldrich syndrome WAS OMIM 301000 Abnormal Ig
levels
Yes Yes WAS Histone methylation
Immunodeficiency syndrome with
hyper-IgM, type 2
HIGM2 OMIM 605258 Yes Aberrant terminal
differentiation
No AID DNA methylation
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dinucleotides. The methyl group is transferred onto DNA
by DNA-methyltransferases (DNMTs). These enzymes can be
grouped into de novo DNMTs (DNMT3A and DNMT3B, which
establish DNA methylation patterns) and maintenance DNMTs
(DNMT1, which has a preference for hemi-methylated DNA and
follows the replication fork to restore DNA CpG methylation on
the hemi-methylated DNA after synthesis of the daughter strand).
Cytosine methylation is a mark that can also be erased, in this
case by proteins of the ten-eleven-translocation (TET1-3) family.
There are genome areas, known as CpG islands, enriched in
CpG dinucleotides, that concentrate near gene promoters. CpG
cytosines in CpG islands are usually unmethylated in normal
conditions, and this is generally associated with active gene
transcription. CpG island methylation leads to gene repression
and is often associated with tumoral progression. Therefore,
correct CpG methylation patterns are essential for maintaining
precise gene expression during development and differentiation.
Histone Modifications
In vivo, DNA is coiled around histones, forming chromatin; the
different histones can suffer several types of post-transcriptional
modifications (methylation, acetylation, phosphorylation,
ubiquitination, SUMOylation, etc.) on different amino acid
residues (Lys, Ser, Thr, Arg) in several positions along the
polypeptide chain, and to different degrees (e.g., mono-, di-, and
trimethylation). The majority of these marks can also be removed
by the corresponding enzymes (demethylases, deacetylases, etc.).
Cross-talk between different histone modifications can take place
within the same histone polypeptide tail or among different tails
and in coordination with other marks in adjacent nucleosomes.
In fact, very often the enzymes that make a certain modification
are also readers capable of detecting previous marks. In this way,
the final functional outcome of histone modifications depends
on how the combination of all these marks is interpreted by
reader and effector proteins, therefore constituting the so-called
“histone code.”
Chromatin Remodelers
Nucleosome positioning and, subsequently, DNA accessibility
can be modified by other additional mechanisms besides
histone modification. In eukaryotes there are four families
of ATP-dependent chromatin remodelers (SWI/SNF, ISWI,
NURD/Mi-2/CHD, and INO80/SWR1), capable of affecting
chromatin architecture by repositioning nucleosomes and
forming nucleosome-free regions along the DNA, therefore,
allowing the access of the transcription machinery to the
otherwise condensed genomic DNA. It is however not still clear
to what extent chromatin structure is (in)dependent on DNA
sequence, therefore adding a genetic layer of complexity to this
epigenetic regulation.
Non-coding RNAs
Non-coding RNAs are functional RNA molecules that are
not translated into proteins. There are several structural and
functional types [microRNAs (miRNAs), small nucleolar RNAs
(snoRNAs), PIWI-interacting RNAs (piRNAs), long ncRNAs
(lncRNAs), etc.], and therefore they constitute a heterogeneous
group that includes some molecules with the capacity of
regulating gene expression, although not all of them have a
bona fide epigenetic function (i.e., they do not necessarily confer
heritability of expression patterns) (Peschansky and Wahlestedt,
2014). In general, they can participate, among other functions,
in chromatin remodeling and in transcriptional and post-
transcriptional regulation.
The best characterized ncRNAs are miRNAs, which are 19–
25 nucleotides in length, and control the expression levels of
their target genes through pairing with their corresponding
mRNAs, mostly at the level of their 3′-untranslated regions
(3′-UTRs), resulting in transcriptional repression, mRNA
cleavage, or translational arrest (Gebert and MacRae, 2019).
It is calculated that miRNAs regulate the fine tuning of the
expression of approximately 30% of human genes (Lu and Clark,
2012). MiRNAs are first transcribed in the nucleus as long
transcripts (primary miRNA transcripts, pri-miRNAs), and their
posterior processing involves the action of a series of proteins
including members of the Argonaute family, Pol II-dependent
transcription and the RNase III proteins Drosha and Dicer
(Gebert and MacRae, 2019; Treiber et al., 2019).
Another important regulatory RNA type are lncRNAs, a
highly heterogeneous group of functional molecules that are
generally longer than 200 nucleotides, can be either nuclear or
cytosolic and have little or no coding potential (Peschansky and
Wahlestedt, 2014). They are transcribed in very large numbers
and many of them exhibit significant tissue- and cell-type
specificity, suggesting that they have distinct cellular functions.
Cytoplasmic lncRNAs often act by means of their sequence
complementarity with other transcripts, and they can therefore
modulate translational control (Fatica and Bozzoni, 2014). Also,
they can act as “miRNA sponges,” by binding to and sequestering
specific miRNAs to protect the miRNA target mRNAs from being
repressed (Poliseno et al., 2010). On the other side, nuclear
lncRNAs function by guiding chromatin modifiers to specific
genomic loci (Fatica and Bozzoni, 2014), and when recruiting
DNMT3 and histone modifiers they predominantly correlate
with the formation of repressive heterochromatin (Rinn et al.,
2007; Nagano et al., 2008; Pandey et al., 2008). Alternatively,
transcriptional activation by lncRNAs is also possible, and has
been shown to occur through the recruitment of chromatin-
modifying complexes like histone H3K4 methyltransferases,
or by the activation of specific enhancer regions through
changes in the three-dimensional conformation of chromatin
(Orom et al., 2010; Wang et al., 2011).
Proteins Controlling Three-Dimensional
Chromatin Structure and Long-Range
Chromatin Interactions
Genomic DNA in the nucleus possesses multiple nested levels of
organization, from the double helix primary sequence itself to the
chromosome territories in the nucleus (Krumm and Duan, 2019).
We are still starting to understand the molecular mechanisms
regulating this hierarchical, layered structure, especially at its
highest levels. However, it is becoming increasingly clear that
the proteins responsible for this organization might very well
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be considered as a heritable component of an epigenetic
system regulating the formation of particular higher-order
chromatin structures, and therefore contributing to lineage-
specific patterns of gene expression (Phillips and Corces, 2009).
The most representative example of this type of proteins is
the CCCTC-binding factor (CTCF) that, together with cohesin,
is essential for the delimitation of the boundaries of the
“topologically associated domains” (TADs) that constitute one
of the next levels of organization above nucleosomes (Krumm
and Duan, 2019). TADs are regions of chromosomes with
a high frequency of internal interactions between loci; on
the contrary, loci from different TADs have low interaction
frequency, even when they happen to be close to each other
in the lineal sequence of the chromosome. Therefore, CTCF
and cohesin, through the delimitation of TAD boundaries,
regulate and limit the region that a given enhancer can
affect and contribute to defining the gene expression patterns
(Liu et al., 2019).
Finally, considering epigenetic regulators as a whole, it must
be emphasized that an extreme complexity arises from the
existence of an active cross-talk between all the aforementioned
epigenetic marks among themselves, and also with transcription
factors and other cellular structural proteins, in such a way that
changes in one epigenetic mark are usually followed by a cascade
of other epigenetic alterations, which can also be propagated
laterally along chromatin.
A CORRECT EPIGENETIC REGULATION
IS ESSENTIAL FOR THE NORMAL
DEVELOPMENT AND FUNCTION OF
IMMUNE CELLS
Hematopoiesis is the developmental process that generates all
the different cell types that form the blood (Cedar and Bergman,
2011; Brown et al., 2018). Given the scope of this review, we
will very briefly describe the importance of epigenetic regulation
at the different stages of B-cell development, which has been
extensively reviewed elsewhere (Busslinger and Tarakhovsky,
2014; Cullen et al., 2014; Zan and Casali, 2015a; Bao and
Cao, 2016; Martin-Subero and Oakes, 2017), although innate
immunity is also strongly regulated at the epigenetic level
[excellently reviewed in Zhang and Cao (2019)]. Multipotent
hematopoietic stem cells (HSCs) will give rise to all blood
cell types thanks to their ability to self-renew and differentiate
toward multiple lineages. This process is very tightly controlled
by epigenetic regulators that lead to the choice of the different
cellular identities through mechanisms that are still intensely
studied (Cullen et al., 2014). Alterations in any of the different
types of epigenetic regulation that control these processes at
the root of blood cell generation usually have catastrophic
consequences and lead to severe diseases, very frequently
leukemias (Hu and Shilatifard, 2016). For example, the miR-17–
92 cluster expands multipotent hematopoietic progenitors, while
the imbalanced expression of its individual miRNAs promotes
leukemia in mice (Li et al., 2012).
Hematopoietic stem cells will gradually give rise to a
continuum of low-primed undifferentiated (CLOUD)-
hematopoietic stem (HS)/progenitor cells (HS/PCs),
progressively acquiring a lineage priming into the main
groups of blood cell types (Brown et al., 2007; Velten et al., 2017).
The differentiation of B lymphocytes is a multistep process that
starts is the bone marrow, where lymphoid-primed multipotent
progenitors will give rise to common lymphoid progenitors
(Murre, 2018). These will commit to the B-cell lineage with the
expression of transcription factors like the lineage-specifying
factors E2a and Ebf1 and the lineage-commitment factor Pax5.
This lymphoid gene priming is antagonized by the H3K27
methylation mediated by the Polycomb-repressive complex
1 (PRC1), which promotes HSC renewal and function. In
addition, both PRC1 and PRC2 silence Ebf1 and Pax5 in
lymphoid progenitors by establishing the repressive histone
marks H2AK119ub1 and H3K27me3 at their promoters. B-cell
transcription factors will therefore act as pioneering factors
and, with the help of chromatin and nucleosome remodelers,
will lead to the appearance of a B-lineage-specific chromatin
accessibility and particular DNA methylation patterns (Li et al.,
2018; Miyai et al., 2018).
B-cell progenitors will then give rise to committed pro-
B cells, which will undergo DJ and V(D)J rearrangements at
the immunoglobulin heavy chain locus. These rearrangements
are the basis of adaptive immunity and have the potential of
creating chromosomal abnormalities and, as such, they are tightly
regulated. The reaction is mediated by the lymphoid-specific
recombination-activating proteins RAG1 and RAG2, with the
help of other cofactors and the DNA repair machinery; in
fact, many classical PIDs of a very clear genetic origin are
caused by deficiencies in DNA repair proteins (Slatter and
Gennery, 2010) leading to inefficient repair of immunoglobulin
genes. However, the temporal and spatial control of gene
rearrangements is marked by the sequential opening of
chromatin that exposes specific recombination signal sequences
(RSSs) to the recombinases (Busslinger and Tarakhovsky, 2014),
which is in turn mediated by a combination of histone
marks, intergenic antisense transcription and DNA methylation
changes that modify the contraction and the compaction of
the immunoglobulin locus to make recombination possible
(Daniel and Nussenzweig, 2012). Also, the V(D)J recombination
process requires a precise looping of chromatin to allow the
right interactions between the recombining regions that can
be megabases apart, in a process that is controlled in part
by interaction with CTCF and cohesin (Guo et al., 2011;
Hu et al., 2015).
Pro-B cells will become pre-B cells, expressing the rearranged
Igµ chain in a complex with surrogate light chains, forming the
pre-B receptor; then they will rearrange the immunoglobulin
light chain and become immature B cells expressing the mature
immunoglobulin (B-cell receptor, BCR) on the cell surface.
These processes are controlled by many factors, among them,
miRNAS; for example, it has recently been shown in mice
that the miR-17–92 family miRNAs control the pro-B to pre-
B cell transition in a cell-autonomous manner, and that the
complete absence of this miRNA family leads to increased
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apoptosis of pre-B cells (Lai et al., 2016). Similarly, knocking
out the Dicer protein resulted in a differentiation block at the
pro- to pre-B cell transition in mice (Koralov et al., 2008),
not surprisingly since many miRNAs seem to be involved in
controlling this important developmental step (de Yebenes et al.,
2013). Afterward, immature B cells will leave the bone marrow
and mature into naïve B cells in the peripheral hematopoietic
organs. In time, they will be activated by the encounter with their
cognate antigen and the interactions with antigen-presenting
cells, and they will become germinal center (GC) B cells in
the follicles in spleen and lymph nodes. For this process, it is
necessary the correct expression of the major histocompatibility
complex II (MHC-II), a process that is dependent on the
right chromosomal conformation and therefore requires CTCF
(Majumder and Boss, 2010; Majumder et al., 2014), which is also
required for the maintenance of the GC center transcriptional
program and to prevent premature differentiation of GC B cells
into plasma cells (Perez-Garcia et al., 2017). In the GC, B cells will
undergo the processes of class-switch recombination (CSR) and
somatic hypermutation (SHM), by which they will generate the
different immunoglobulin isotypes with their specific functions
(IgGs, IgA, IgE), and they will mature the affinity of the
antibodies to greatly increase their specificity. A key player
in this GC B-cell-specific process is the activation-induced-
deaminase protein (AID), capable of catalyzing cytosine-to-
uracil deaminations on single-stranded DNA mainly at Ig genes,
to create U:G mismatches which, when repaired by different
means, will lead to CSR and SHM. Once more, this process is
dependent on many complex and coordinated changes in histone
marks, transcription, DNA methylation, and global chromatin
organization (Sheppard et al., 2018). Also, through modulating
the expression of AID and Blimp-1 (which is required for
plasma cell differentiation and antibody production) miRNAs
can regulate SHM and CSR in B cells. For example, miRNAs
miR-155, miR-181b, and miR-361 can silence AID expression
(de Yebenes et al., 2008; Borchert et al., 2011; Basso et al., 2012;
Fairfax et al., 2015), while miR-30a and miR-125b can silence
Blimp-1 expression (Gururajan et al., 2010; Wang et al., 2013),
by interacting with evolutionary conserved target sites in the 3′-
UTR of their mRNAs. Also lncRNAs play a very important role at
this stage, regulating the humoral immune response at different
levels and with different functions, being tightly regulated and
specifically expressed in each stage of the response (Agirre et al.,
2019). Finally, at the end of the GC reaction, B cells will give rise
to immunoglobulin-secreting plasma cells or long-lived memory
cells that will form the immunologic humoral memory.
MUTATIONS IN EPIGENETIC
REGULATORS INTERFERING WITH
LYMPHOCYTE DEVELOPMENT IN
HUMAN PRIMARY
IMMUNODEFICIENCIES
It is therefore clear that immune development is strongly
regulated at the epigenetic level and that, consequently, any
alteration affecting epigenetic modifiers can have serious effects
in the differentiation and/or function of the cells of the immune
system. In fact, congenital alterations of epigenetic modifiers,
given their importance, affect many tissues in the organism and,
therefore, they usually give rise to complex syndromes where ID
is one of the associated pathologies. The number of mutations
identified in epigenetic regulators associated with human PIDs
has progressively increased in the last years (Campos-Sanchez
et al., 2019). The proteins or nucleic acids mutated can be
involved in any of the different types of epigenetic processes
that we have described above (Table 1) and can interfere with
lymphocyte development at different (sometimes multiple) stages
of their differentiation.
In Wolf–Hirschhorn syndrome (WHS), hemizygous deletion
of WHSC1 (encoding a H3K36 mono- and di-methyltransferase,
Table 1) had been proposed to be associated with the increased
susceptibility to infections. Recently, experiments in Whsc1+/−
and Whsc1−/− mice have demonstrated that decreased levels
of this enzyme lead to an impaired B-cell function (Campos-
Sanchez et al., 2017). First, Whsc1−/− pro-B cells have very
low levels of expression of transcription factors Ebf1 and
Pax5, strictly required for specification and commitment to the
B-cell lineage (see above), and therefore the differentiation to
the pre-B-cell stage is greatly impaired. Second, the reduced
numbers of B cells that reach the mature stage in the spleen
present a plethora of alterations (replicative stress, DNA damage
accumulation, impaired proliferation) that prevent them from
correctly performing the CSR reaction, therefore, leading to
a reduced production of mature immunoglobulin subtypes,
exactly as seen in human patients (Hanley-Lopez et al., 1998;
Campos-Sanchez et al., 2017).
In the patients suffering from Roifman syndrome,
together with other serious developmental defects, the B-cell
differentiation block occurs at the transitional B-cell stage,
and leads to a severe reduction in the numbers of circulating
B cells (Heremans et al., 2018). This syndrome is caused by
compound heterozygous mutations in the small nuclear RNA
gene RNU4ATAC (Table 1), necessary for the splicing of specific
subtypes of introns (Merico et al., 2015). As a consequence,
intron splicing of many genes does not occur correctly, and
this includes genes necessary for the correct development of B
cells, like the one encoding mitogen-activated protein kinase 1
(MAPK1), required for survival signaling necessary during B-cell
differentiation (Heremans et al., 2018).
In ID–centromeric instability–facial anomalies syndromes
(ICFs, numbered 1–4), mutations in different genes affecting
converging pathways (Table 1) interfere with the correct
establishment and maintenance of CpG methylation at
centromeric repeats (Hansen et al., 1999; Xu et al., 1999; de
Greef et al., 2011; Thijssen et al., 2015), therefore leading to many
defects in gene expression. This causes a dysregulation of genes
involved in the correct development of lymphocytes, which
seem to especially interfere with the latest stages of lymphocyte
maturation (Ehrlich et al., 2001; Ehrlich, 2003).
Kabuki syndrome can present (as identified so far, since the
genetic basis of the syndrome remains unknown in 20–45% of
patients) two different underlying molecular defects (Table 1),
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but both of them epigenetically affect the gene activation
machinery, functioning to either add active marks or to remove
repressive ones from histone H3 and, therefore, they affect
many downstream genes (Ng et al., 2010; Lederer et al., 2012;
Cheon and Ko, 2015). Among them, are the immunoglobulin
genes, which require correct histone H3 methylation patterns
for their rearrangements during B-cell development (Daniel and
Nussenzweig, 2012). Consequently, Kabuki patients have reduced
numbers of memory B cells and decreased levels of SHM. This
leads to defects in long-term immunological memory and to
reduced antibody affinity (Lindsley et al., 2016). In fact, as it
happens for many others PIDs of other molecular origins, also
in the case of alterations in epigenetic regulators, one of the
steps of B-cell development most frequently affected is the GC
reaction and the process of CSR. This is not surprising since the
GC reaction requires the orchestrated action of many molecular
players and it also implies major chromatin reorganization at
different levels (Zan and Casali, 2015b). We have already seen
that Whsc1 deficiency interferes with correct CSR at many
levels. Another epigenetic regulator recently described as being
responsible for CSR defects in some human PIDs is INO80, the
catalytic ATPase subunit of the INO80 chromatin-remodeling
complex, required for the correct resolution of the CSR process,
probably at the level of DNA repair (Kracker et al., 2015;
Poli et al., 2017).
Another example of an epigenetic regulator altered in
syndromic PIDs is KMT2A, found mutated in nearly 100% of
the cases of Wiedemann–Steiner (WS) syndrome (Jones et al.,
2012; Table 1). KMT2A encodes the H3K4 methyltransferase
MLL, an essential regulator of hematopoietic development
frequently altered in infant B-acute lymphoblastic leukemia
(Milne et al., 2002). Due to its low incidence, the precise
nature of the B-cell developmental defect in WS has not yet
been clarified, but patients present increased urinary tract,
respiratory, and ear infections associated with low concentrations
of immunoglobulins (Stellacci et al., 2016).
Although less frequent in this group, epigenetic defects also
can affect T-cell development and/or function, leading to a
deficient immune cellular response or, due a to an inefficient
stimulation of B cells, to a reduced or altered T-cell dependent
humoral response and immunoglobulin production. Schimke
immuno-osseous dysplasia (SIOD) is caused by mutations in
the SMARCAL1 gene, which encodes a chromatin-remodeling,
DNA annealing helicase that collaborates in the maintenance of
genomic integrity by participating in DNA replication fork restart
and DNA repair (Boerkoel et al., 2002; Bansbach et al., 2009).
SIOD patients present normal B-cell numbers, but abnormal
immunoglobulin levels, because they have decreased T-cell
numbers (Table 1; Boerkoel et al., 2002). This is believed to be
due to the fact that the IL7Rα promoter is hypermethylated in
T cells from SIOD patients, and therefore they have reduced
IL7Rα expression, consequently rendering T cells less responsive
to IL-7, which is necessary for their correct development
(Sanyal et al., 2015).
Another very complex syndrome with associated ID is
CHARGE (coloboma of the eye, heart defects, atresia of the
choanae, retardation of growth, genital and ear abnormalities)
syndrome, caused by mutations in the CDH7 gene, encoding
a chromatin remodeler that catalyzes nucleosome translocation
along chromatin. The ID in CHARGE is mainly due to the
presence of low numbers of peripheral T cells; however, it is
not still clear whether this defect is T-cell autonomous, since
CHARGE patients may present with thymic aplasia and a severely
reduced thymic function (Wong et al., 2015). In any case, despite
normal peripheral B-cell differentiation and immunoglobulin
production in all patients, 83% of patients had insufficient
antibody titers to one or more early childhood vaccinations,
presumably due to insufficient T-cell help during the CSR process
(Wong et al., 2015).
Here we have just briefly summarized the most relevant
human conditions in which genetic alterations in epigenetic
modifiers have been found associated with immunological
defects. The list of other pathological conditions that can arise
in humans as a consequence of other similar mutations is quite
large (Berdasco and Esteller, 2013; Brookes and Shi, 2014), and
it shows the enormous importance of epigenetic regulators for
the correct development and function of the organism. Similarly,
experiments in genetically engineered knockout mice lacking
defined epigenetic regulators has shown that many on them are
indeed essential for immune system development and function,
a finding that most probably could be extrapolated to humans if
the lack of these genes wasn’t most likely lethal during embryonic
development (Cullen et al., 2014).
THE EPIGENOME IS ALTERED BY BOTH
EXOGENOUS AND ENDOGENOUS
FACTORS IN SECONDARY
IMMUNODEFICIENCIES
Almost all epigenetic marks identified so far have been shown
to be physiologically reversible (i.e., dedicated cellular enzymes
exist that are in charge of either adding or removing every
given epigenetic modification). Like any other cellular process,
epigenetic regulation is also exposed to different types of
environmental or internal insults and, therefore, the epigenome
can be altered in many ways, either directly by external agents
or indirectly downstream of other cellular processes affected
(Jasiulionis, 2018; Tzika et al., 2018). These alterations will
consequently interfere with normal cellular development and/or
function, and are at the root of SIDs. SIDs result from the adverse
consequences on the immune system of exposure to a variety of
factors like age (prematurity or aging), infectious agents, drugs,
metabolic diseases, malnutrition, trauma (splenectomy, burns),
stress (hypoxia, sleep disturbance), environmental conditions
(UV light, radiation, hypoxia, space flight), etc. (Chinen and
Shearer, 2010). The coming of age of epigenomics and the
new technological developments in this field are revealing
the existence of epigenetic modifications associated to the
exposure to most of these factors, as we describe below with
specific examples.
Pathogens are obviously strong modifiers of the immune
system. One of the most extreme cases in humans is of course
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human immunodeficiency virus (HIV), since it kills essential
cells of the immune system and therefore depletes the body’s
defenses, beyond its own infectivity (Chinen and Shearer, 2010).
However, many other microorganisms have also profound effects
in the cells of the immune system by directly modifying the
chromatin of their host, either through pathogen-encoded gene
products or through changes in expression of host chromatin
modifiers (Paschos and Allday, 2010). It is increasingly clear
that viruses exploit cellular epigenetic processes to control their
life cycles during infection (Balakrishnan and Milavetz, 2017).
For example, influenza viruses can use viral histone mimics to
interfere with the formation of transcriptional complexes and
gene expression, in such a way that the immunosuppressive
NS1 protein of influenza A virus uses histone mimicry for the
suppression of antiviral gene expression (Schaefer et al., 2013).
In other family of viruses, herpes simplex viruses (HSVs) use
specific histone modifications to control viral gene expression
during latency (Kubat et al., 2004), so that the initiation of
infection requires the activity of histone demethylases LSD1 and
JMJD2 to promote transcriptional activation of viral genes (Liang
et al., 2013). In fact, pharmaceutical inhibition of the activity
of JMJD2 represses the expression of HSV immediate–early
genes and blocks the infection (Liang et al., 2013). Something
similar happens with the human cytomegalovirus latency and
reactivation processes, which have been shown to be regulated by
H3K9 and H3K27 histone methyltransferases and demethylases
(Abraham and Kulesza, 2013; Gan et al., 2017). These and other
examples from other types of viruses (Balakrishnan and Milavetz,
2017) show the importance of epigenetic regulation of viral
infections and open the door to the potential development of
new antiviral therapies based in the use of epigenetic drugs
(Kristie, 2012; Nehme et al., 2019).
Viruses are not the only pathogens that possess this epigenetic
capacity; the intracellular bacteria Listeria monocytogenes can
dephosphorylate histone H3 and deacetylate histone H4 during
the early phases of infection by means of the toxin listeriolysin
O (Hamon et al., 2007), and another Listeria protein, InlB, can
induce the translocation of the human histone deacetylase SIRT2
into the host cell nucleus, resulting in deacetylation of H3K18
and repression of many cellular genes, including immune-
regulatory genes (Eskandarian et al., 2013). Shigella flexneri, a
Gram-negative bacterium, blocks histone H3 phosphorylation
at designated promoters by injecting a phosphothreonine lyase
into epithelial cells (Arbibe et al., 2007). The Shigella protein
OspF enters the nucleus and indirectly blocks histone H3
phosphorylation at Ser10 (Arbibe et al., 2007; Harouz et al.,
2014). This results in repression of a set of genes that includes
IL8, among others. By downregulating IL8 expression, OspF
can interfere with neutrophil recruitment in infections in vivo
(Arbibe et al., 2007).
Not only infectious microbes have the possibility of
epigenetically modifying the human immune response; the
commensal microbiota is also a strong regulator of the immune
system (Wingard, 2018), and its correct composition throughout
infancy and later life is essential for the appropriate development
of a functioning immunity (Tamburini et al., 2016). These effects
can be mediated by the microbes themselves (e.g., via metabolites
such as short chain fatty acids, biotin, folic acid) or by immune
mediators like cytokines (Wingard, 2018), and part of the effects
of these bioactive metabolites is epigenetically mediated and can
affect DNA methylation, histone modifications, and ncRNAs
(Gerhauser, 2018; Qin and Wade, 2018). Since it is mainly
located in the gut, the effects and composition of the microbiota
are intertwined with those of the diet; indeed, although this field
of research is still in its infancy, it is clear that the components
of the diet, either directly or after being metabolized by the gut
microbiota, have the capacity of epigenetically modifying the
cells of the organism, and to guide the correct development and
function of the immune system (Hardy and Tollefsbol, 2011;
Johnson and Belshaw, 2014; Zhang and Kutateladze, 2018).
Classically, it was assumed that chemicals were able to cause
cancer only by mutating the DNA. However, now we know
that this “carcinogenesis = mutagenesis” paradigm is far from
perfect. Out of 162 chemicals that were found to be carcinogens
by the US National Toxicology Program in 1991, 64 (40%)
were not genotoxic (Ashby and Tennant, 1991), illustrating the
importance of carcinogenic mechanisms other than genotoxicity.
Nowadays it has been ascertained that many environmental
exposures (endocrine disruptors, metals, benzene, hydrocarbons,
tobacco smoke, phytochemicals, etc.) have a strong effect in
epigenetics [reviewed in Stein (2012)]; although the majority of
these effects have been investigated under the light of cancer
research, it is clear that they act in a multisystemic manner and
that they also affect the function of the immune system, similarly
to what happens with the side effects of many therapeutic drugs
(Chinen and Shearer, 2010).
Since, in the end, gene expression changes require epigenetic
modifications, we are progressively finding that epigenetic
changes (at least in the context of molecular epigenetics and
heritability of phenotypes at the cellular scale) underlie any
reaction of the cell in response to a certain condition or
stimulus. For example, it has recently been described that histone
modifiers like histone demethylase KDM6A can sense the oxygen
concentration and that, therefore, hypoxia can signal directly to
chromatin to trigger specific adaptive changes in gene expression
(Chakraborty et al., 2019; Gallipoli and Huntly, 2019). In the
NASA Twins Study, where two identical twins were analyzed
and compared when one of them had stayed in the International
Space Station for a year (Garrett-Bakelman et al., 2019), DNA
methylation analysis revealed epigenetic discordances in the
promoters of several regulators of T-cell differentiation and
activation, associated with down-regulation of the corresponding
genes (Garrett-Bakelman et al., 2019).
All the aforementioned evidences underscore the important
role of epigenetic modifications in the cells of the immune
system in response to exogenous environmental exposures of
different types. An endogenous and well-established cause of
SIDs is aging (Muller et al., 2013). The accumulation of changes
in the organism with age is enormous and its description falls
out of the scope of this review. Among these changes are
alterations in the epigenome that are accumulating over time,
to a large degree in a pseudo-random (since they seem to be
more frequent in some parts of the genome) and progressive
manner, as it has been determined by DNA methylation studies
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of identical twins (Fraga et al., 2005; Zheng et al., 2016).
Regarding the immune system, there is a clear decline in immune
function with age, and both B (Kline et al., 1999; Johnson
et al., 2002) and T cells numbers (Aspinall and Andrew, 2000)
are reduced in both humans and mice as they get old, and
this is correlated with epigenetic alterations at different levels
(Jasiulionis, 2018), both in T (Dozmorov et al., 2017; Suarez-
Alvarez et al., 2017) and in B cells (Wu et al., 2018), causing
different immune defects ranging from ID to autoimmunity.
Furthermore, also HSCs lose their developmental plasticity with
age, and epigenetic deregulation is also associated with this
process (Chambers et al., 2007; Kramer and Challen, 2017).
AN EPIGENETIC-ONLY MECHANISM
CAN BE RESPONSIBLE FOR SOME
HUMAN IMMUNODEFICIENCIES
Altered epigenetic patterns can therefore be generated, as
we have described, by many different mechanisms. Because
of their epigenetic nature, once they have arisen they can
be self-perpetuating and then lead to the appearance of
aberrant cellular lineages with altered functions or with
changed susceptibilities to otherwise normal stimuli. As we
have mentioned regarding mutagens, in cancer research, for
many years, only genetic mutations affecting the DNA sequence
were considered as the drivers of cancer. Nowadays, however,
we know that epigenetic priming has an essential role in the
origin and evolution of most types of tumors (Murtha and
Esteller, 2016; Vicente-Duenas et al., 2018). Although very
frequently there are cancer-initiating mutations altering the
coding sequence of epigenetic regulators, their posterior effects
are, to a large degree, epigenetically mediated, and become
independent on the initiating genetic mutations (Vicente-
Duenas et al., 2013, 2018; Simo-Riudalbas and Esteller, 2014).
Furthermore, we now know that even the first steps of tumor
initiation can be fully epigenetically mediated in some cases
(Mack et al., 2014; Bartlett et al., 2016; Fang et al., 2016;
Sanders et al., 2018).
In spite of the fact that new genes involved in IDs are
progressively being identified, especially with the spreading of
the use of NGS techniques, there are many cases where relevant
mutations cannot be found (Kienzler et al., 2017; de Valles-Ibanez
et al., 2018). In fact, NGS studies have only managed to identify
potentially pathogenic mutations in 30–60% of the CVID patients
(Stray-Pedersen et al., 2017; Abolhassani et al., 2018), and this
has led to the conclusion that many cases of CVID are likely to
be due to polygenic causes in which the combination of many
genetic variants leads to the appearance of this therefore highly
variable disease (van Schouwenburg et al., 2015; Maffucci et al.,
2016; de Valles-Ibanez et al., 2018). This had also been previously
proposed on basis of the results from genome-wide association
studies (GWASs) (Orange et al., 2011).
We have seen that epigenetic priming can be a driver
of IDs, and that alterations in essential epigenetic regulators
can cause severe malfunctions of the immune system. Also,
we now know that proteins with well-established activities
can turn out to also have epigenetic functions that might
be important in IDs, like in the case of Wiskott–Aldrich
(WA) protein in WA syndrome or AID in ID syndrome with
HIGM, type 2 (Table 1) [discussed in Campos-Sanchez et al.
(2019)]. The evidences that we have presented so far paint
the possibility of a picture analogous to the role of epigenetics
in cancer for the development of at least some human IDs.
This would imply the existence of certain epigenetic profiles
that can trigger or promote the development of ID but are
not due to mutations in epigenetic regulatory genes, but are
in fact caused by internal or environmental epigenetically
primed events. Along these lines, performing high-throughput
DNA methylation analyses in monozygotic twins discordant
for CVID, it has been shown that there is a gain of DNA
methylation in affected B cells with respect to those from
the unaffected sibling (Rodriguez-Cortez et al., 2015). This
results in the hypermethylation of critical B-cell genes like
PIK3CD, BCL2L1, RPS6KB2, TCF3, or KCNN4. The posterior
study of the methylation status of these genes in naïve,
unswitched, and switched memory B cells in a cohort of
CVID patients showed an impaired capacity to demethylate and
upregulate them in the differentiation from naive to memory cells
(Rodriguez-Cortez et al., 2015).
Summarizing, we have seen how a genetic mutation can
inactivate an epigenetic regulator, therefore leading to a priming
that modifies the development and/or function of the affected
cell type(s). If the penetrance of the mutation is high, then the
appearance of the ID is just a matter of time once the mutation
is present (and they are usually congenital). If the penetrance is
lower, then the ID may appear or not, or be more or less serious,
depending on the presence of other modifying genes or on the
exposure to specific insults.
In the absence of an inactivating genetic mutation, the
combination of certain genetic variants might predispose the
epigenome of certain cells, and make them more responsive to
environmental or internal factors that might end up causing
ID. This dependence on exposures could be the reason of the
differences often found in identical twins.
Finally, in a healthy person without any previous genetic,
epigenetic, or multifactorial predisposition, exposure to
environmental factors, like the ones we have described before,
could trigger epigenetic changes that can lead to ID or, with time,
can make this person more predisposed to develop ID later in life,
either spontaneously or upon encounter with additional agents.
This gradient of possibilities that we have just summarized,
and the evidences that we have presented, leads us to propose
that an epigenetic-only mechanism could be responsible for
some subsets of human IDs (which could be called “epigenetic
immunodeficiencies”, EIDs), and that the frontier between
primary and SIDs, although useful from a clinical point of
view, might be in some cases more blurred than usually
proposed, at least at the molecular level (Figure 1). This idea
implies the existence of a “tridimensional” gradient (Figure 1)
of intermediate types of IDs with a mixed and variable
contribution of (i) genetic, (ii) environmental, and (iii) epigenetic
causes, which is in fact a continuum landscape of all possible
combinations of these factors.
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FIGURE 1 | An epigenetic perspective on the early stages of human
immunodeficiencies (IDs). (A) Traditionally, two main variables have been
considered for the major subdivision of human IDs: initiated by genetic causes
(“x”-axis) or by external exposures∗ (“y”-axis). Therefore, purely primary
immunodeficiencies (PID, blue circle) would be at the rightmost end of the
x-axis and purely secondary immunodeficiencies (SID, green circle) would be
at the upper end of the y-axis (circle sizes do not intend to represent accurate
percentages). There is also a gradient of intermediate cases with a mixed,
variable, contribution of genetic and environmental causes, and most
probably this gradient, represented here with smaller blue–green circles, is in
fact a continuum of possible combinations. Additionally, in many cases, the
etiology of IDs is still uncertain (represented by a gray circle). (B) Now we have
evidences showing that epigenetics constitutes a third underlying “z”-axis (in
gradations of red) complementary and subjacent to the previous ones. In both
PIDs and SIDs, epigenetics can play a role in the initiation or the manifestation
of the disease (see main text), with a degree of contribution that can vary
among diseases (green–red and blue–red spheres), and also during the
evolution of the disease. The most extreme case would be that of IDs
triggered only by epigenetic alterations (Epigenetic ID, EID, red sphere at the
end of the z-axis). In any case, also in this 3D scheme, the spheres represent
points in what most likely is a continuum landscape of possible combinations
contributing to the development of human IDs. ∗External exposures in a broad
sense (aging, infections, etc., see main text).
OUTLOOK AND FUTURE PROSPECTS
If epigenetic changes constitute a “third axis” in the etiology
and progression of human IDs (Figure 1), then they might also
provide a potential target for the management of the disease. On
one side, they can be used as biomarkers for diagnostic or to
evaluate the response to treatment (Berdasco and Esteller, 2019).
This would be feasible if we could identify certain epigenomic
signatures as being associated with the exposure to specific
agents [similarly to what is quickly becoming a standard
with mutational signatures in cancer (Alexandrov et al., 2013;
Kucab et al., 2019)] or with a given underlying genetic
condition. This is in fact becoming real with the latest
advances in epigenomics, especially with the most tractable of
epigenetic modifications, DNA methylation. Indeed, examining
the methylome in peripheral blood samples from a cohort
of individuals suffering 1 of 14 different Mendelian disorders
caused by mutations in epigenetic regulators (among them,
CHARGE and Kabuki), it has been found that specific DNA
methylation signatures are associated with many of these
conditions (Aref-Eshghi et al., 2018). Furthermore, there is
almost no overlap among these epi-signatures, suggesting that,
given a certain initial event, the downstream changes that
arise are unique to every syndrome (Aref-Eshghi et al., 2018).
In fact, genomic DNA methylation analysis can be powerful
enough to make possible the molecular diagnosis of unresolved
clinical cases of these disorders when conventional genetic
testing doesn’t provide informative results (Barbosa et al., 2018;
Aref-Eshghi et al., 2019).
This type of diagnostic biomarker approach is still in its
infancy for SIDs, with only some preclinical examples for
the detection of hepatitis B virus (Pollicino et al., 2006) or
HIV (Kumar et al., 2015) infections, but the aforementioned
success for more complex syndromes indicate its feasibility.
Also, research into the mechanisms by which a given exposure
results in a certain type of ID, and the epigenetic changes
associated with it, might allow establishing prophylactic measures
to help preventing the development of the pathology. In
the context of immunology, epigenomic maps have been
elaborated for complex inflammatory diseases like systemic lupus
erythematosus (Wang et al., 2017), for autoimmune diseases
such as multiple sclerosis (Zheleznyakova et al., 2017) and for
other disorders like allergies (Potaczek et al., 2017). Clearly,
there are still barriers to translate these findings to the clinic,
such as the variability of the epigenome among the different
cell types (especially important when analyzing whole blood),
the small numbers of patients affected of every specific disease,
or the genetic and epigenetic heterogeneity among patients that
makes difficult to distinguish normal from pathological variants.
The best way to address these problems would be to perform
studies on monozygotic twins; however, these are extremely
rare. Therefore, the generation of animal models of human
IDs will be one of the best systems to identify reproducible
epigenomic changes affecting specific cell types, with minimal
variability among samples.
The next step should of course be the use of epigenetic
drugs (epidrugs, for the so-called pharmacoepigenetics) for
the treatment of those IDs where epigenetic changes are
important for the origin or progression of the disease.
Today many epidrugs are being tested in cancer, and small
molecule inhibitors already exist capable of targeting the
main types of epigenetic regulators: DNMT inhibitors, histone
acetyltransferase inhibitors, histone methyltransferase inhibitors,
histone deacetylase inhibitors, histone demethylase inhibitors,
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and others (Berdasco and Esteller, 2019). Once more, these
approaches will have to be first tested in appropriate animal
models, in conceptual proof-of-principle experiments, most
likely using conditional gene activation/inactivation in vivo;
initially one would have to determine the degree of reversibility (if
any) of the altered epigenome to a normal, functional epigenome
in immunodeficient animal models, and if this reversion is
paralleled by a return to a healthy condition, in what would
also be a preclinical model of response to treatment. Later,
either selective or genome-wide (depending on the disease)
epigenetic drugs or targeted gene therapy methods will be
required for therapeutic reprogramming, in an approach that
could be potentially be later translated to the clinic.
Another important aspect, especially in the context of SIDs,
will be to determine the existence of potential (epi)genetic
susceptibility to given exposures that could therefore be avoided
in a prophylactic intervention. If we could determine if a
particular individual is susceptible of developing ID in response
to exposure to a certain disease or to a given agent (something
still very difficult today, for the reasons mentioned before), then
prophylactic measures could be implemented to avoid those risks.
Additionally, epigenetic therapies could be initiated to prevent or
to revert pathologic priming toward disease.
In summary, we believe that epigenetic reprogramming is an
important player in the origin and progression of IDs, and should
be taken into account on equal terms with genetic mutations and
exposure to external agents for the classification and, especially,
for the study of these diseases. There are still many cases where
the molecular cause of IDs is unknown. Although a very large
part of those will most probably be due to yet undetected
mutations in key genes or to polygenic conditions, the evidences
strongly suggest the existence of IDs that might be caused only
by epigenetic alterations. Furthermore, the role of epigenetic
alterations in a large number of what today are classified as PIDs
or SIDs is also undeniable. Therefore, taking into account this
epigenetic priming will be important not only conceptually, but
also for the future development of diagnostic, prophylactic, and
therapeutic interventions that can improve the health and quality
of life of people susceptible to or affected by IDs.
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